ROCHELLE PARK, N.J., Jan. 15, 2008 (PRIME NEWSWIRE) -- According to an independent study published in the Lancet in October 2007, carperitide (human atrial natriuretic peptide) significantly reduced cardiac death and re-hospitalization for heart failure in acute myocardial infarction (AMI), when used as an adjunct to percutaneous coronary intervention (PCI). Carperitide is a compound that has been marketed for more than a decade in Japan for the treatment of acute heart failure and is available for licensing in the U.S. and Europe.
